Viatris (VTRS) Long-Term Debt Repayments (2020 - 2025)
Viatris (VTRS) posted quarterly Long-Term Debt Repayments of $100000.0 for Q4 2025, down 99.99% year-over-year from $1.4 billion in Q4 2024, and down 99.99% quarter-over-quarter from $1.4 billion in Q4 2024.
Viatris (VTRS) Long-Term Debt Repayments (2020 - 2025) Analysis & Trends
Viatris' Long-Term Debt Repayments history runs 6 years deep, the most recent figure standing at $100000.0 for Q4 2025.
- In Q4 2025, Long-Term Debt Repayments fell 99.99% year-over-year to $100000.0; the TTM figure through Dec 2025 stood at $2.9 billion (down 21.58% YoY), while the FY2025 annual figure was $100000.0, down 100.0% from the prior year.
- Long-Term Debt Repayments for Q4 2025 stood at $100000.0, down from $1.4 billion in the prior quarter.
- The five-year high for Long-Term Debt Repayments was $2.3 billion in Q2 2021, with the low at $100000.0 in Q1 2022.
- The 5-year median for Long-Term Debt Repayments is $801.7 million (2024), against an average of $986.8 million.
- The sharpest annual moves came in 2023 and 2025: Long-Term Debt Repayments surged 750000.0% in 2023, then tumbled 99.99% in 2025.
- Viatris' Long-Term Debt Repayments stood at $600000.0 in 2021, then jumped by 116666.67% to $700.6 million in 2022, then fell by 28.62% to $500.1 million in 2023, then surged by 174.81% to $1.4 billion in 2024, then sank by 99.99% to $100000.0 in 2025.
- Business Quant data shows VTRS's Long-Term Debt Repayments at $100000.0 in Q4 2025, $1.4 billion in Q4 2024, and $1.5 billion in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -156,847.56 |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 100,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 1.37 Bn |
| Dec 31, 2024 | 1.37 Bn |
| Sep 30, 2024 | 1.54 Bn |
| Sep 30, 2024 | 1.54 Bn |
| Jun 30, 2024 | 801.70 Mn |
| Jun 30, 2024 | 801.70 Mn |
| Dec 31, 2023 | 500.10 Mn |
| Dec 31, 2023 | 500.10 Mn |
| Mar 31, 2023 | 750.10 Mn |
| Mar 31, 2023 | 750.10 Mn |
| Dec 31, 2022 | 700.60 Mn |
| Dec 31, 2022 | 700.60 Mn |
| Sep 30, 2022 | 1.17 Bn |
| Sep 30, 2022 | 1.17 Bn |
| Jun 30, 2022 | 1.79 Bn |
| Jun 30, 2022 | 1.79 Bn |
| Mar 31, 2022 | 100,000.00 |
| Mar 31, 2022 | 100,000.00 |